Advaxis announces revised survival data in Phase 1/2 ADXS-PSA Trial
Category: #healthcare  By Mateen Dalal  Date: 2019-10-09
  • share
  • Twitter
  • Facebook
  • LinkedIn

Advaxis announces revised survival data in Phase 1/2 ADXS-PSA Trial

Drugs used for the treatment of various diseases are only made available in the market after confirmation of its safety and efficacy in patients enrolled in its clinical trials. Clinical studies indicate possibility of better outcomes for a given treatment. Information from such clinical trials are also vital for developing new therapies.

Advaxis Inc. (ADXS), an American biotech company devoted for development, discovery, and commercialization of immunotherapy products, has reportedly announced updated median overall survival data of its Phase 1/2 KEYNOTE-046 clinical trial in metastatic, castration-resistant prostate cancer, or mCRPC.

Sources cite that this clinical trial is conducted with Merck and is assessing ADXS-PSA, the company’s Lm-based immunotherapy, alone and in combination with KEYTRUDA ® (pembrolizumab), Merck’s anti-PD-1 therapy.

According to the previous data presented at the American Association for Cancer Research (AACR) Annual Meeting in April, the median overall survival for patients was 21.1 months in the combination arm. However, at the final data cutoff of 16 Sept. 19, the updated median overall survival for 37 patient suffering from a disease increased to 33.6 months (95% CI, range 15.4 – 33.6 months).

Reportedly, the company will be presenting these updated data and additional details from this clinical trial in the upcoming medical conference.

Speaking on which, Kenneth A. Berlin, Chief Executive Officer and President of Advaxis, stated that the company is excited to present these updated data which showed a considerable increase in median overall survival for 37 patients who were suffering from the disease in the KEYNOTE-046 study.

He said that the company believes that ADXS-PSA, along with KEYTRUDA ®, has the potential to become a vital treatment option for patients who are suffering from advanced metastatic, castration-resistant prostate cancer.

Moreover, Advaxis is currently evaluating future steps for a potential new study for ADXS-PSA in combination with KEYTRUDA ® in mCRPC and would be providing additional details about the program’s future roadmap.

Source Credit - https://ir.advaxis.com/press-release/clinical-data-updates/advaxis-announces-updated-prolonged-survival-data-phase-12-adxs

About Author

Mateen Dalal    

Mateen Dalal

Despite working as a professional testing engineer, Mateen Dalal always held a liking for content creation. Following his passion, he now pens down articles for itresearchbrief.com and a couple of similar portals. Mateen is a qualified electronics and telecommunicat...

Read More>>

More News By Mateen Dalal

Enlitic partners with Select Healthcare for early cancer detection
Enlitic partners with Select Healthcare for early cancer detection
By Mateen Dalal

Artificial Intelligence in healthcare industry is set to be one of the highest revenues generating m...

Harley-Davidson pulls the plug from its electric motorcycle production
Harley-Davidson pulls the plug from its electric motorcycle production
By Mateen Dalal

For years, American motorcycle manufacturer Harley Davidson has been ruling the biking industry. It ...

Convergint Technologies acquires Real Connect to expand in Europe
Convergint Technologies acquires Real Connect to expand in Europe
By Mateen Dalal

Service based system integration firms are witnessing a substantial growth recently due to the integ...